Thursday, 28 October 2010
Commenting on the results, David Brennan, Chief Executive Officer, said:
We remain firmly on track to achieve our full year financial targets. The third quarter performance featured double-digit revenue growth in Emerging Markets. Revenue also increased in Western Europe and Established Rest of World. As expected, the impact of generic competition on several products and the absence of pandemic flu vaccine revenue led to a challenging quarter in the US.”
Third quarter and nine months results 2010
Announced on Thursday 28 October 2010